Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Release of Emails from Johnson & Johnson’s Janssen Subsidiary in Federal Risperdal Settlement

The Firm is evaluating potential Risperdal lawsuits on behalf of individuals who may have suffered from gynecomastia, or male breast growth, allegedly due to their use of Risperdal.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Free Case Review
A number of Risperdal lawsuits, including many that involve gynecomastia, have been filed in recent years that allege Johnson & Johnson and Janssen concealed Risperdal side effects. Considered in that light, these emails are very interesting.

New York, New York (PRWEB) November 17, 2013

As Risperdal lawsuits (http://www.therisperdallawsuit.com/ ) over allegations that use of drug may cause gynecomastia, or male breast growth, continue to move forward, Bernstein Liebhard LLP notes that the U.S. Department of Justice has released several internal emails from Johnson & Johnson’s Janssen Pharmaceutical subsidiary that raise questions about the company’s disclosure of Risperdal clinical trial data. In one such email from 2003, a researcher expresses concern about “clinical trial data the company has been sitting on since for a long time,” and urges Janssen to “publish not just the clinical efficacy data which should very well be informative and supportive of the use of” Risperdal, but “also the safety data, including events that have been labeled in the past as ‘cerbrovascular adverse events’ and death.”*

According to Bernstein Liebhard, another email from 2004 seems to indicate that Janssen may have been reluctant to disclose unfavorable data from another Risperdal study. “At this point, we must be concerned that this gives the strong appearance that Janssen is purposely witholding (sic) the findings from RIS 232,” the writer warns. “I really do have to speak out and urge that Janssen avoids embarrassment and accusations about suppressing information that is relevant to providers and consumers.**

“A number of Risperdal lawsuits, including many that involve gynecomastia, have been filed in recent years that allege Johnson & Johnson and Janssen concealed Risperdal side effects. Considered in that light, these emails are very interesting,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Risperdal lawsuit consultations to any individual who may have developed gynecomastia due to Risperdal.

Risperdal Lawsuits
Risperdal is an antipsychotic medication that has been on the market since 1993. Court records indicate that 250 Risperdal lawsuits, including many that allege a connection between Risperdal and gynecomastia, are currently pending in a consolidated litigation underway in the Pennsylvania Court of Common Pleas in Philadelphia. Among other things, plaintiffs in Risperdal gynecomastia lawsuits allege that Johnson & Johnson downplayed Risperdal’s association with male breast growth, and accuse the company of improperly marketing the drug for use in children. (Risperdal Litigation, case number 100300296)

The emails in question where released by the U.S. Department of Justice when it announced earlier this month that Johnson & Johnson and its Janssen unit had agreed to pay $2.2 billion to settle criminal and civil charges regarding the improper marketing of Risperdal and other drugs. Among other things, the companies were accused of misbranding Risperdal and promoting off-label use of the drug for children, elderly nursing home patients, and those with mental disabilities. According to the Justice Department, Risperdal was not approved for any pediatric uses until 2006. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Alleged victims of Risperdal and gynecomastia may be entitled to compensation for injury-related damages, including medical bills, lost wages and pain and suffering. To learn more about Risperdal, including the potential side effects of Risperdal in children, please visit Bernstein Liebhard LLP’s website. For a free legal review, please call 800-511-5092.

*justice.gov/opa/documents/jj/20131031_Risperdal/civ-exhibit8-redacted.pdf
**justice.gov/opa/documents/jj/20131031_Risperdal/civ-exhibit9-redacted.pdf

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.therisperdallawsuit.com/
https://plus.google.com/115936073311125306742?rel=author